Erroneous formulation of delayed-release omeprazole capsules: alert for importing countries

Mohammad Sofiqur Rahman 1*, Naoko Yoshida 1, Hirohito Tsuboi 1, Tep Keila 2, Tey Sovannarith 2, Heng Bun Kiet 3, Eav Dararth 3, Theingi Zin 4, Tsuyoshi Tanimoto 5 and Kazuko Kimura 1

Abstract

Background: Poor drug quality is a matter of serious concern, especially in countries where drug regulation and law enforcement are constrained by limited resources. This study was carried out to investigate the cause of quality failure of omeprazole in Cambodia in 2010 and Myanmar in 2014.

Methods: We conducted pharmacopoeial quantity, content uniformity and dissolution tests of 156 samples of omeprazole capsules collected in Cambodia in 2010 and Myanmar in 2014. High failure rates were found, especially in dissolution testing, and detailed investigation of several unacceptable samples was carried out by means of in-vitro dissolution profiling, scanning electron microscopy (SEM) and X-ray computed tomography (X-ray CT) to identify the cause of failure.

Results: Dissolution profiling with and without the acid stage showed that acid caused premature omeprazole release, indicating that the enteric coating of the omeprazole granules was ineffective. SEM examination of two failed samples revealed cracked and broken granules mixed with apparently intact omeprazole granules in the capsule. X-ray CT examination indicated that some granules of failed samples completely lacked enteric coating, and others had incomplete and non-uniform enteric coating or malformation.

Conclusions: Omeprazole capsules collected in Myanmar and Cambodia showed high failure rates in pharmacopoeial tests, especially dissolution tests. Some samples were found to have ineffective or absent enteric coating of the granules, resulting in premature dissolution and degradation in acidic conditions. This is a potentially serious public health issue that needs to be addressed by regulatory authorities in Cambodia and Myanmar, possibly through a collaborative initiative with manufacturers.

Keywords: Substandard, Omeprazole, Enteric coating, Myanmar, Cambodia

Background

There is considerable evidence that the incidence of falsified and substandard medicines is increasing, particularly in middle- and lower-income countries [1–3]. There have been many well-established instances of spurious, falsely labeled, falsified or counterfeit (SFFC) medicines in recent years [4–10]. In addition, substandard medicines, which are prepared by legitimate manufacturers but fail to meet pharmacopoeial requirements, also constitute an enormous public health problem [11–15]. On-going surveillance seems essential.

The substituted benzimidazoles are a class of antisecretory compounds that suppress gastric acid secretion by inhibition of the H⁺/K⁺-ATPase enzyme system at the secretory surface of gastric parietal cells [16, 17]. Among them, omeprazole, 5-methoxy-2-[[4-methoxy-3,5-dimethyl-2-pyrinylmethyl-sulfinyl]-1H-benzimidazole, is a basic compound that acts as a proton pump inhibitor, and is used in the treatment of acid reflux and heartburn [18]. It is acid-labile, being degraded rapidly in aqueous solution at low pH [19, 20]. Pre-formulation studies confirmed that it is susceptible to moisture, heat and acidic conditions, which could lead to degradation and loss of potency.
solvents [21, 22]. Therefore, to avoid degradation of omeprazole by acid in the stomach, the drug must be enteric-coated [23, 24]. Consequently, omeprazole dosage forms are prepared and marketed in an enteric-coated form that allows the omeprazole core to be specifically released and dissolved in the duodenum (pH > 5) or terminal ileum where the pH is about 6.8 to 7.5 [25].

Despite increasing attention to the quality of medicines for communicable diseases, [6]. The availability of falsified and substandard medicines in Myanmar was reported by WHO in 1999 [15], but since then there has been no systematic survey in the country, and the current situation is unclear, except for sporadic reports of falsified medicines. Based on our experience in Cambodia during 2006-2013 [6], where we encountered various poor quality (mostly substandard) medicines, omeprazole was chosen as one of the target medicines for investigation in Myanmar, in consultation with the Department of Food and Drug Administration (FDA), Myanmar. Among 156 samples of omeprazole capsules collected in Cambodia in 2010 and Myanmar in 2014, we found high failure rates in pharmacopeial tests, especially dissolution tests. This is broadly consistent with other reports of substandard drugs in Cambodia [26, 27].

The aim of the present study was to establish the cause of the high failure rate of omeprazole capsules from the two countries in dissolution tests by means of detailed evaluation of the in-vitro dissolution profile, as well as scanning electron microscopy (SEM) and X-ray computed tomography (X-ray CT) examinations.

**Methods**

**Materials**

United States Pharmacopeia (USP) reference standard omeprazole was procured from USP Convention. Authentic omeprazole standard capsules (Losec) were provided by AstraZeneca. Lansoprazole (internal standard) was from Sigma Aldrich (India). NaH₂PO₄·2H₂O, Na₃HPO₄, Na₃PO₄, KH₂PO₄ and other chemicals of reagent grade were purchased from Nacalai Tesque Inc. (Kyoto, Japan). Distilled water was used for the preparation of HPLC eluents.

The investigational samples consisted of 154 samples of hard gelatin capsules containing 20 mg of omeprazole in enteric-coated pellets and 2 tablet samples purchased from different drug stores in Cambodia in 2010 and Myanmar in 2014. In Cambodia, samples were collected from pharmacies, depots, wholesaler and outlets of Phnom Penh, Svay Rieng and Kandal provinces. In Myanmar, collected samples were from pharmacy, hospital, and wholesalers of Yangon region. These samples of different serial and batch number were imported to Cambodia and Myanmar from 53 different manufacturers in seven countries. Samples were stored below 25°C after collecting and all the quality analysis of the samples was finished before the expiration date of the samples. After quality-testing as required by the indicated pharmacopoeia, we selected five samples for further investigation based on the gravity of their failure in the dissolution test.

**HPLC determination of omeprazole**

To assess the pharmaceutical quality of the omeprazole samples, the active ingredient was detected by a simple reverse phase high performance liquid chromatography (HPLC). HPLC was run on a Phenomenex Gemini NX C18 column (150 × 4.6 mm), with a Prominence HPLC Photo Diode Array Detector (SPD-20A/20AV Series; Shimadzu, Kyoto, Japan). The temperature of the column oven was set to 25°C. Elution buffer was prepared by dissolving 1.17 g NaH₂PO₄·2H₂O and 1.06 g Na₃HPO₄ in 1000 ml of water; the pH was adjusted to 6.8. The column was eluted with a mixture of phosphate buffer and acetonitrile (60:40) at a flow rate of 0.5 ml/min. Detection wavelength and injection volume were 302 nm and 10 μL, respectively for British Pharmacopoeia (BP) samples. For USP samples, the flow rate was 1 ml/min, detection wavelength was 280 nm, and injection volume was 10 μL. The system suitability for the analysis of omeprazole was verified according to USP 37. The limit of detection (LOD) and limit of quantification (LOQ) of omeprazole was determined by the slope of the calibration curve and the standard deviation of responses. For each linearity solution of 5 different concentrations, average area of the multiple injections (n = 3) were taken and graph of concentration in μg/ml (X-axis) versus peak area response (Y-axis) was plotted. LOD and LOQ concentrations of omeprazole were determined on the basis of equation,

\[
\text{Limit of Detection} = 3.3 \times \sigma / S,
\]

and

\[
\text{Limit of Quantification} = 10 \times \sigma / S
\]

Where, \(\sigma\) = the standard deviation of the response

\(S\) = the slope of the calibration curve

A linear relationship between the peak area and concentration of each reference standard was observed within the range of 25–200% of the active ingredient \((r^2 = 0.999–1.000)\), and the assay was performed within that range. In addition, the method was validated as being repeatable and accurate \((n = 6)\).
Omeprazole quantity and content uniformity tests

Quantity and content uniformity tests of omeprazole samples were carried out according to the modified method of BP 2010 and 2015 [28, 29] or USP 34 and 37 [30, 31] as indicated in the package insert or on the outer package of each sample. For the identification test, a chromatogram of the sample was compared with that of reference standard omeprazole. The retention time of the principal peak in the sample chromatograms was similar to that of the peak of standard omeprazole. Standard solutions were prepared by dissolving accurately weighed quantities of omeprazole (reference standard) and lansoprazole (internal standard) in the diluent to obtain solutions with concentrations of 0.2 mg/mL and 0.1 mg/mL, respectively. From these stock solutions, five diluted omeprazole solutions (0.2, 0.15, 0.1, 0.05 and 0.025 mg/mL) were prepared. The relationship between the peak area and concentration of each reference standard was linear within the range of 25–200% of the active ingredient ($r^2 = 0.999–1.000$), and the quality test was performed within that range.

In the quantity test, acceptance criteria of omeprazole for BP samples were as follows: tablets/capsules contain the equivalent of not less than 95.0% and not more than 105.0% of the labeled amount of omeprazole. For USP samples, the acceptance range was between 90–110%. The acceptance value for the content uniformity test was ≤15. In the dissolution test, the maximum percentage of omeprazole allowed to be dissolved in the acid stage for BP samples was the average of 24 units is not more than 10% and no individual unit is not more 25% of omeprazole dissolved. For USP samples, the tolerance in the acid stage was the average of 24 units is not more than 20% of omeprazole dissolved, not more than two units are greater than 35% of omeprazole dissolved and no individual unit is greater than 45% of omeprazole dissolved. In the buffer stage, the acceptance criterion for BP samples was the average value of 24 units is equal to or greater than Q ($Q = 65\%$), not more than 2 units are less than Q-15% & no unit is less than Q-25% ($Q = 75\%$).

Omeprazole dissolution test and examination of dissolution profile

The dissolution test was performed according to the BP or USP as indicated by the sample products. BP Samples were exposed to 700 mL phosphate buffer, pH 4.5, for 45 min in acid stage and 900 mL phosphate buffer, pH 6.8 for 45 min in buffer stage [28, 29]. USP samples were exposed to 500 mL of 0.1 N HCl for 2 h in acid stage and 900 mL of phosphate buffer, pH 6.8 for 30 min in buffer stage [30, 31]. The dissolution test was conducted with a NTR-VS 6P dissolution apparatus (Toyama Sangyo Co., Ltd., Osaka, Japan). Drug release studies were carried out by paddle method. The paddle was set to rotate at 100 rpm and the temperature was maintained at 37 ± 0.5 °C.

To examine the dissolution profile, three capsules were used. Since all the failed samples were BP samples, in the investigation with the acid stage, test samples were exposed to 700 mL phosphate buffer, pH 4.5, for 45 min. After 45 min, a 5 mL aliquot was withdrawn from each vessel for quantification by HPLC. Then 200 mL of phosphate buffer, pH 7.6, was added to adjust the final pH to 6.8 (buffer stage). In this stage, 5 mL aliquots were withdrawn from each dissolution vessel at 5, 15, 30, 45, and 60 min for quantification by HPLC. In the investigation without the acid stage, samples were exposed to the buffer stage directly without the previous acid stage, and samples were collected in the same manner as described above.

Scanning electron microscopy

Surface morphology of omeprazole granules was characterized by means of scanning electron microscopy on a Hitachi S-3400 instrument equipped with a Hitachi E-1010 ion sputter device. A few omeprazole granules were removed

Table 1

| Country        | Shop category | No. of samples (n/%) | Country of manufacturer | Quality tests | Acceptable n/% | Unacceptable n/% | Pending* n/% |
|----------------|---------------|----------------------|-------------------------|---------------|----------------|------------------|-------------|
|                |               | Domestic (n/%)        | Imported (n/%)           |               |                |                  |             |
| Cambodia 2010  | Pharmacy      | 26/28.5              | 2/2.2                   | Quantity      | 54/59.3        | 22/24.2          | 15/16.5      |
| (n = 91)       | Depot         | 45/49.5              | 89/97.8                 | Content Uniformity | 31/34.1        | 14/15.4          | 46/50.5      |
|                | Wholesaler    | 8/8.8                |                         | Dissolution   | 42/46.2        | 45/49.4          | 4/4.4        |
| Myanmar 2014   | Pharmacy      | 35/53.8              | 0/0                     | Quantity      | 42/64.6        | 23/35.4          | 0/0          |
| (n = 65)       | Hospital      | 26/40                | 65/100                  | Content Uniformity | 56/86.2        | 9/13.8           | 0/0          |
|                | Wholesaler    | 4/6.2                |                         | Dissolution   | 48/73.8        | 17/26.2          | 0/0          |

*Insufficient material was available for full testing
from the capsule shell, mounted on a stub of metal with adhesive, coated with platinum, and observed.

**X-Ray computed tomography**

X-Ray CT of the samples was conducted using an inspeXio SMX-100CT (Shimadzu) equipped with a sealed tube type micro focus X-ray generator with a maximum output of 100 kV, and a high-sensitivity image intensifier. The sample granules were positioned between the X-ray generator and the X-ray detector, and X-ray fluoroscopic data was collected from every angle by rotating the sample through 360°. Finally, computed tomographic images (CT images) were calculated from the obtained data.

![Fig. 1 Dissolution profiles (percent release) of omeprazole in buffer stage with and without acid stage.](image)

**Fig. 1** Dissolution profiles (percent release) of omeprazole in buffer stage with and without acid stage. **a** The standard sample; **b** one failed omeprazole sample (B-040) from Cambodia; **c** two failed omeprazole samples from Myanmar. Each value represents mean ± SD of three capsules except for (b) where \( n = 1 \). Significant differences were evaluated \((**p < 0.01)\) comparing percent dissolution of the capsules in with and without acid stage at each time point using student's t-test. For the dissolution profile of Cambodian sample only one capsule was used in each stage, the result of which was not available for statistical comparison.
Fig. 2 HPLC chromatogram of omeprazole samples in acid resistance stage. a Omeprazole reference standard; b standard omeprazole sample; c passed omeprazole sample; and d failed omeprazole sample
Statistical Analysis
Statistical analyses were performed using Microsoft Excel and SPSS 19.0.0 (IBM SPSS Inc. Chicago, IL, USA). Statistical differences between the experimental groups were analyzed by Student’s \( t \)-test. Statistical significance was evaluated at the 5% level.

Results
Quality analysis of collected samples
Among the 156 omeprazole samples collected, 45 (28.8%) were unacceptable in the quantity test, while 23 (14.7%) were unacceptable in the content uniformity test. In the dissolution test, 90 samples (57.7%) were acceptable and 62 (39.7%) were unacceptable (Table 1).

Dissolution profile: Effect of the acid stage on drug release
Figure 1 (a) shows the percent of omeprazole released in buffer from a standard sample (Losec) with and without the acid stage; in this case, the enteric coating of the granules retained its integrity in the acid stage, as expected, and the percent release of omeprazole without the acid stage was not much different from the percent release of omeprazole with the acid stage. Figure 1 (b) and (c) show the percent of drug released from the omeprazole granules of one Cambodian sample and two Myanmar samples respectively. In these cases, the pattern of drug release in buffer without the acid stage was significantly higher than that with the acid stage, suggesting that the enteric coating of the failed samples was not fully effective.

Acid degradation of omeprazole
Typical chromatograms of reference standard omeprazole, standard omeprazole, a passed omeprazole sample and a failed omeprazole sample are shown in Fig. 2. The failed sample showed peaks indicating that degradation had occurred.

To confirm this, reference standard (pure) omeprazole was exposed to acid (pH 4.5) and aliquots were withdrawn for HPLC analysis at 0, 10, 30, and 45 min. As shown in Fig. 3, peaks of degradation products increased time-dependently, and the time course of remaining omeprazole is shown in Fig. 4. These results are consistent with the conclusion that the failed omeprazole samples lacked effective enteric coating.

Variability of granules in samples
Considerable variability related to the formulation or manufacturing process of omeprazole has been suggested in Cambodian samples [6], and we found similar variation in some Myanmar samples. The shape of the granules ranged from spherical to irregular, and different-colored granules were seen, as illustrated in Fig. 5. We isolated white, yellow, and grey granules, and
The omeprazole contents in the white, grey and yellow granules were 64.1 ± 0.2, 61.4 ± 0.5 and 42.7 ± 1.7 mg (mean ± SD) per 267.8 mg of granules (average weight of six granules).

**Examination of granules by scanning electron microscopy**

Representative SEM images are shown in Fig. 6. Compared with the standard sample (a), granules from failed omeprazole samples collected in Cambodia in 2010 showed cracks in the enteric coating, along with the broken pellets. These were mixed with the regular granules in the capsule.

**Examination of granules by X-ray computed tomography**

To confirm the absence of functional enteric coating, we performed X-ray CT on selected samples that failed severely in the dissolution test and conducted a comparative study of the standard sample and failed samples.
Figure 7 shows two different granules taken from the same capsule in a sample collected in Cambodia in 2010. One granule shows an apparently intact coating (Fig. 7a), while the other (Fig. 7b) has essentially no coating at all. Similar results were seen in failed samples from Myanmar, which contained non-uniform granules, incomplete granules, and granules with holes. Figure 8 shows representative X-ray CT images of granules from a failed Myanmar sample.

Discussion
Our findings for samples collected in Myanmar in 2014 indicate that the incidence and condition of substandard omeprazole medicines in Myanmar are quite similar to those in Cambodia. Yoshida et al. found that 45 out of 91 omeprazole samples collected in Cambodia in 2010 (49.5%) were unacceptable in the dissolution test (Table 1) [6]. Among the Myanmar samples, 23 (35.4%) failed the quantity test, although the extent of failure was generally marginal. A few failed due to over-content. Moreover, significant differences were observed in the quality test, where some brands passed in most cases, while others were consistently substandard. It was particularly noteworthy that the products of certain manufacturers failed consistently.

In the present work, our prime concern was the failures in dissolution tests. Among the 17 (26.2%) unacceptable samples from Myanmar, all failed in the buffer stage and 11 failed in both the acid and buffer stages. A key issue appeared to be that the coating of the granules did not provide good control of the drug release, so that rapid disintegration and dissolution
occurred in the acid stage of the test, resulting in exposure of omeprazole to acid degradation [17, 19, 32, 33]. Indeed, an HPLC analysis showed that degradation of omeprazole in the granules of failed samples during the acid stage was similar to that of pure omeprazole (Fig. 3), confirming that the enteric coating was ineffective.

This conclusion was further supported by SEM images (Fig. 6), which revealed fractured pellets and pellets with incomplete coating, together with pellets with apparently intact coating. Macroscopically, a sample from Cambodia contained two different types of granules in a single capsule, and the X-ray CT images showed that one type of granule lacked enteric coating (Fig. 7). Similar results were found in a sample from Myanmar, which appeared to contain three different types of granules (Fig. 5). The X-ray CT images revealed that the coating of some granules was incomplete and some granules contained holes (Fig. 8). Thus, there was marked inconsistency among omeprazole granules in capsules, and this suggests that at least some manufacturers were using inadequate enteric coating technology or conditions. However, we were unable to confirm this with the manufacturers. Substandard medicines are a serious public health issue. In the case of omeprazole, substandard samples without enteric coating or with incomplete enteric coating will degrade rapidly in the acidic environment of the stomach after oral administration, and this may result in treatment failure.

It should be noted that in some cases the size of our samples was insufficient for detailed examination, and this represents a weakness of our study, in that we could not fully assess the actual extent of quality failure in our analysis. Another limitation is that; we could not confirm the coating material used during the manufacture of the enteric coated pellets or if there was inadequate coating method (e.g. inadequate equipment or inadequate coating parameters) as the response to the questionnaire from the manufacturers was minimum. Therefore, further investigation is needed to establish precisely the scale of the problem of substandard medicines in Myanmar and Cambodia. In addition, action, including regulatory measures, should be initiated to prevent the manufacture and sale of substandard medicines.

**Conclusions**

Samples of omeprazole capsules collected in Cambodia in 2010 and Myanmar in 2014 showed high failure rates in pharmacopoeial testing, especially in the dissolution test. In-vitro dissolution profiling, scanning electron microscopy and X-ray computed tomography showed that failed samples contained granules with ineffective (cracked or incomplete) or absent enteric coating. This
would result in premature dissolution in acidic conditions after oral administration, and could result in treatment failure. This situation is a potentially serious public health issue that needs to be addressed by regulatory authorities in Cambodia and Myanmar, possibly through legal measures and collaborative initiatives with manufacturers.

Abbreviations
BP: British Pharmacopoeia; DDF: Department of Drugs and Food; FDA: Food and Drug Administration; HPLC: High-performance liquid chromatography; JPMA: Japan Pharmaceutical Manufacturers Association; NF: National Formulary; SEM: Scanning electron microscopy; USP: United States Pharmacopoeia; WHO: World Health Organization; X-CT: X-Ray computed tomography

Acknowledgements
The authors are grateful for the support of Japan Pharmaceutical Manufacturers’ Association (JPMA) and member companies for this project. Without cooperation and efforts of JPMA, this project would not have been possible, though they had no role in the study design, experiments, the decision to publish, or preparation of the manuscript. We are grateful to Ministry of Health, Labour and Welfare (MHLW), Japan for their help in SEM analysis. We thank National Institute for Materials Science (NIMS), Japan for their help in X-Ray CT analysis. We also thank Department of Drugs and Food (DDF), Cambodia and FDA, Myanmar for their kind support and cooperation. Authors are thankful to AstraZeneca for providing Losec capsules.

Funding
This study was conducted with financial support from Japan Pharmaceutical Manufacturers’ Association (JPMA) received by KK, http://www.jpma.or.jp/english/. The funding body had no role in study design, data collection, and analysis, decision to publish, or preparation of the manuscript.

Availability of data and materials
All data generated or analysed during this study are included in this published article.

Authors’ contributions
MSR participated in the study design, carried out the experimental study, analysis and drafted the manuscript. NY, HT, TS, and TT designed the study and analyzed the experimental data. TK, TS, HBK, TZ and KK designed and coordinated the study. ED designed the study. All authors helped to prepare the draft and approved the final manuscript.

Authors’ information
Drug Management and Policy, Kanazawa University, 920-1192 Kanazawa, Japan, Mohammad Sofiqi Rahman, PhD student, Naoko Yoshida, Assistant Professor, Hirohito Tsuibo, Associate Professor, Kazuko Kimura, Professor, National Health Product Quality Control Center, 12112 Phnom Penh, Ministry of Health, Cambodia, Tep Keila, Director, Tey Sovannarith, Deputy Director, Department of Drugs and Food, 12000 Phnom Penh, Ministry of Health, Cambodia, Heng Bun Kiet, Director, Eav Darath, Inspector, Department of Food and Drug Administration, Ministry of Health, Myanmar, Thein Myint Zin, Director, Faculty of Pharmaceutical Sciences, Doshisha Women’s University, 610-0395 Kyoto, Japan, Tsyoshi Tanimoto, Professor.

Competing interests
The authors declare that they have no competing interests.

Consent to publish
Not applicable.

Ethics approval and consent to participate
Not applicable.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Drug Management and Policy, Kanazawa University, Kanazawa, Japan.
2National Health Product Quality Control Center, Ministry of Health, Phnom Penh, Cambodia. 3Department of Drugs and Food, Ministry of Health, Phnom Penh, Cambodia. 4Department of Food and Drug Administration, Ministry of Health and Sports, Naypyidaw, Myanmar. 5Faculty of Pharmaceutical Sciences, Doshisha Women’s University, Kyoto, Japan.

Received: 26 December 2016 Accepted: 27 April 2017
Published online: 03 May 2017

References
1. Almuzaini T, Choonara I, Sammons H. Substandard and counterfeit medicines: a systematic review of the literature. BMJ Open 2013. doi:10.1136/bmjopen-2013-002923.
2. Newton PN, Green MD, Fernandez FM. Impact of poor-quality medicines in the “developing” world. Trends Pharmacol Sci. 2010. doi:10.1016/j.tips.2009.11.005.
3. Caudron JM, Ford N, Henkens M, Macé C, Riddle-Monroe R, Pinel J. Substandard medicines in resource-poor settings: a problem that can no longer be ignored. Trop Med Int Health 2008. doi:10.1111/j.1365-3156.2008.02106.x.
4. Tabernero P, Mayxay M, Cuboni MJ, Divwedi P, Swamidoss I, Allan EL, et al. A Repeat random survey of the prevalence of falsified and substandard antimalarials in the Lao PDR: A change for the better. Am J Trop Med Hyg. 2015. doi:10.4269/ajtmh.15-0057.
5. Khurebat D, Dorj G, Bayarsaikhan E, Chimedsuren M, Sanijav T, Morimoto T, et al. Prevalence estimates of substandard drugs in Mongolia using a random sample survey. SpringerPlus. 2014. doi:10.1186/2193-1801-3-709.
6. Yoshida N, Khan MH, Tabata H, Dararat E, Sovannarith T, Kiet HB, et al. A cross-sectional investigation of the quality of selected medicines in Cambodia in 2010. BMC Pharmacol Toxicol. 2014. doi:10.1186/2050-6511-15-13.
7. Khohaj HMJ, Fallos H, Yoshida N, Akazawa M, Tsuboi H, Kimura K. The quality of medicines in community pharmacies in Riyadh, Saudi Arabia: A lot quality assurance sampling (LQAS)-based survey. Pharmacoł Pharm. 2013. doi:10.4236/pp.2013.4.7047.
8. Kuramoto N, Yabe D, Kurose T, Seino Y. A case of hypoglycemia due to illegitimate sexual enhancement medication. Diabetes Res Clin Pract. 2015. doi:10.1016/j.diabres.2015.02.079.
9. Wang F, Yu S, Liu K, Chen FE, Song Z, Zhang X, et al. Acute intracranial inflammation caused by endotoxin after intravitreal injection of counterfeit bevacizumab in Shanghai, China Ophthalmolology. 2013. doi:10.4284/ojophtha.2012.07.083.
10. Attaran A, Barry D, Barheer S, Bate R, Benton D, Chauvin J, et al. How to achieve international action on falsified and substandard medicines. BMJ 2012. doi:10.1136/bmj.e7381.
11. Kaur H, Goodman C, Thompson E, Thompson KA, Masanja I, Kachur SP, et al. Nationwide survey of the quality of antimalarials in retail outlets in Tanzania. PLoS ONE 2008. doi:10.1371/journal.pone.0003403.
12. Onwujeke O, Kaur H, Dike N, Shu E, Uzochukwu B, Hanson K, et al. Quality of antimalarial drugs provided by public and private healthcare providers in south-east Nigeria. Malar J. 2009. doi:10.1186/1475-2875-8-22.
13. Counterfeit medicines: Some frequently asked questions. Fact sheet, 5 May 2011. doi:10.1039/c0an00627k.
14. Fernandez FM, Hostetler D, Powell K, Kaur H, Green MD, Mildenhall DC, et al. Poor quality drugs: grand challenges in high throughput detection, countrywide sampling, and forensics in developing countries. Analyst. 2012. doi:10.1039/cb110627k.
15. World Health Organization, Counterfeit and substandard drugs in Myanmar and Vietnam: Report of a study conducted in cooperation with the Governments of Myanmar and Vietnam. 1999. http://apps.who.int/medicinedocs/pdf/s2276e/s2276e.pdf. Accessed 6 Dec 2015.
16. Riedel A, Leopold CS. Quantification of omeprazole degradation by enteric coating polymers: an UV-VIS spectroscopy study. Pharmazie. 2005;60(2):126–30.
17. Qaisi AM, Tutunji MF, Tutunji LF. Acid decomposition of omeprazole in the absence of thiol: A differential pulse polarographic study at the static mercury drop electrode (SMDE). J Pharm Sci. 2006. doi:10.1002/jps.20546.
18. Hardman JG, Limbird LE, Gilman AG. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 10th ed. New York: McGraw-Hill; 1996.
19. Mathew M, Gupta VD, Bailey RE. Stability of omeprazole solutions at various pH values as determined by High Performance Liquid Chromatography. Drug Dev Ind Pharm. 1995. doi:10.3109/03639049509026660.

20. Pilbrant A, Cederberg C. Development of an oral formulation of omeprazole. Scand J Gastroenterol. 1985. doi:10.3109/00365528509095824.

21. Davidson AG, McCallum A. A survey of the stability of omeprazole products from 13 countries. Drug Dev Ind Pharm. 1996. doi:10.3109/03639049609063235.

22. Lindberg P, Brandstrom A, Wallmark B. Structure-activity relationships of omeprazole analogs and their mechanism of action. Trends Pharmacol Sci. 1987. doi:10.1016/0165-6147 (87)90107-6.

23. Migoha CO, Ratansi M, Kaale E, Kagashe G. Preformulation studies for generic omeprazole magnesium enteric coated tablets. Biomed Res Int. 2015. doi:10.1155/2015/307032.

24. Bharate SS, Bharate SB, Bajaj AN. Interactions and incompatibilities of pharmaceutical excipients with active pharmaceutical ingredients: a comprehensive review. J Excipients Food Chem. 2010;1:3–26.

25. Thoma K, Bechtold K. Enteric coated hard gelatin capsules. Capsugel. 2000;145:1–17.

26. Khan MH, Okumura J, Sovannarith T, Nivanna N, Akazawa M, Kimura K. Prevalence of counterfeit anthelmintic medicines: a cross-sectional survey in Cambodia. Trop Med Int Health 2010. doi:10.1111/j.1365-3156.2010.02494.x.

27. Khan MH, Okumura J, Sovannarith T, Nivanna N, Nagai H, Taga M, Yoshida N, Akazawa M, Tanimoto T, Kimura K. Counterfeit medicines in Cambodia: possible causes. Pharm Res. 2011. doi:10.1007/s11095-010-0289-1.

28. British Pharmacopoeia Commission. British Pharmacopeia 2010.

29. British Pharmacopoeia Commission. British Pharmacopeia 2015;3:913–915 & 917–918.

30. The United States Pharmacopoeial Convention. USP 34 NF 29. Rockville, The USPC Board of Trustees; 2011.

31. The United States Pharmacopoeial Convention. Rockville: The USPC Board of Trustees. USP 37 NF 32 2014;3:4063–4067.

32. Davidson AG, McCallum A. A survey of the stability of omeprazole product from 13 countries. Drug Dev Ind Pharm. 1996. doi:10.3109/03639049609063235.

33. Jee UK, Lee GW, Jeon UJ. Stability and dissolution enhancement of omeprazole by pharmaceutical technology. J Kor Pharm Sci. 1992;22:281–87.